Physiological function of cyclic nucleotide phosphodiesterases in atrial myocytes and their potential as therapeutic targets for atrial fibrillation
American Journal of Physiology-Cell Physiology · 2025
DOI: 10.1152/ajpcell.00782.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2025. Verfasst von Matthew John Read und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Atrial Fibrillation, Myocytes, Cardiac, Heart Atria, 3',5'-Cyclic-AMP Phosphodiesterases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 355 Literaturangaben. Gefördert von: Wellcome Trust (WT), British Heart Foundation (BHF).
Abstract (Originalsprache)
Cyclic nucleotide hydrolyzing phosphodiesterases (PDEs) are key regulators of cyclic nucleotide (e.g., cAMP and cGMP) signaling. Here, we examine the role of PDEs in the physiology of atrial myocytes (AMs), the pathogenesis of atrial fibrillation (AF), and the potential of PDEs as therapeutic targets for AF. PDE1–5 and 8 are present and functional in AMs. PDE2-4 are important regulators of AM contraction but their role beyond atrial contractility is unclear. The role of PDE1,5 and 8 in healthy AMs is unknown but of interest because of their roles in ventricular myocytes. We propose that PDE2-5 and PDE8 are potential targets to prevent the triggering of AF considering their effects on Ca 2+ handling and/or electrical activity. PDE1–5 are possible targets to treat patients with paroxysmal or persistent AF caused by pulmonary vein automaticity. PDE8B2 is a possible target for patients with persistent AF due to its altered expression. Research should aim to identify the presence, localization, and function of specific PDE isoforms in human atria. Ultimately, the paucity of PDE isoform-specific small molecule modulators and the difficulty of delivering PDE-targeted medications or therapies to particular cell types limit current research and its application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
- Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
- University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Matthew John Read, Andreas Koschinski, Samuel Jitu Bose, Rebecca A B Burton
Förderung
- Wellcome Trust (WT)
- British Heart Foundation (BHF)
Zitieren
APA
Read, M. J., Koschinski, A., Bose, S. J., & Burton, R. A. B. (2025). Physiological function of cyclic nucleotide phosphodiesterases in atrial myocytes and their potential as therapeutic targets for atrial fibrillation. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00782.2024
Vancouver
Read MJ, Koschinski A, Bose SJ, Burton RAB. Physiological function of cyclic nucleotide phosphodiesterases in atrial myocytes and their potential as therapeutic targets for atrial fibrillation. American Journal of Physiology-Cell Physiology. 2025. doi:10.1152/ajpcell.00782.2024
BibTeX
@article{Read2025,
author = {Read, Matthew John and Koschinski, Andreas and Bose, Samuel Jitu and Burton, Rebecca A B},
title = {Physiological function of cyclic nucleotide phosphodiesterases in atrial myocytes and their potential as therapeutic targets for atrial fibrillation},
journal = {American Journal of Physiology-Cell Physiology},
year = {2025},
doi = {10.1152/ajpcell.00782.2024}
}
EUVIMED